Daniel Lochner Net Worth

The estimated Net Worth of Daniel Lochner is at least $2.43 Milión dollars as of 1 November 2021. Mr. Lochner owns over 8,590 units of Oyster Point Pharma Inc stock worth over $650,329 and over the last 5 years he sold OYST stock worth over $0. In addition, he makes $1,780,530 as Chief Financial Officer at Oyster Point Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lochner OYST stock SEC Form 4 insiders trading

Daniel has made over 7 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,590 units of OYST stock worth $98,871 on 1 November 2021.

The largest trade he's ever made was exercising 9,109 units of Oyster Point Pharma Inc stock on 24 February 2021 worth over $104,845. On average, Daniel trades about 3,357 units every 52 days since 2019. As of 1 November 2021 he still owns at least 58,221 units of Oyster Point Pharma Inc stock.

You can see the complete history of Mr. Lochner stock trades at the bottom of the page.

Daniel Lochner biography

Daniel J. Lochner serves as Chief Financial Officer of the Company. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman Sachs where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman Sachs in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an Executive M.B.A. from Columbia University.

What is the salary of Daniel Lochner?

As the Chief Financial Officer of Oyster Point Pharma Inc, the total compensation of Daniel Lochner at Oyster Point Pharma Inc is $1,780,530. There are 2 executives at Oyster Point Pharma Inc getting paid more, with Jeffrey Nau having the highest compensation of $4,037,700.

What's Daniel Lochner's mailing address?

Daniel's mailing address filed with the SEC is C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 106, PRINCETON, NJ, 08540.

Insiders trading at Oyster Point Pharma Inc

Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... a Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.

What does Oyster Point Pharma Inc do?

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

Complete history of Mr. Lochner stock trades at Oyster Point Pharma Inc

Oyster Point Pharma Inc executives and stock owners

Oyster Point Pharma Inc executives and other stock owners filed with the SEC include:

• Jeffrey Nau,
  President, Chief Executive Officer, Director
• John Snisarenko,
  Chief Commercial Officer
• Daniel Lochner,
  Chief Financial Officer
• Dr. Jeffrey Nau Ph.D., MMS,
  Pres, CEO & Director
• Daniel Lochner M.B.A.,
  Chief Financial Officer
• John Snisarenko M.B.A.,
  Chief Commercial Officer
• Mark Murray,
  Director
• Ali Behbahani,
  Chairman of the Board
• Benjamin Tsai,
  Independent Director
• Aimee Weisner,
  Independent Director
• William Link,
  Independent Director
• Clare Ozawa,
  Independent Director
• Tim McCarthy,
  IR Contact Officer
• Michael Atieh,
  Director
• Dr. Marian Macsai M.D.,
  Chief Medical Officer of Medical Affairs
• Loni Da Silva M.S.,
  Sr. VP of Regulatory Affairs
• Raegan A. McClain CCEP, J.D., L.L.M.,
  Chief Compliance Officer
• Barry Rosenfeld J.D.,
  Sr. VP & Gen. Counsel
• Dr. Eric Carlson Ph.D.,
  Chief Scientific Officer
• George Donato M.B.A.,
  Sr. VP of CMC & Operations
• Ventures, Llc Vida,
  10% owner
• Point Pharma I, Llc Oyster,
  10% owner
• Vision Llckkr Healthcare St...,
  
• Gp Iv, L.L.C.Inv Opps Iv, L...,
  
• Michael Ackermann,
  Director
• Perkins Caufield & Byers Xi...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Fund Holdings L.P.Kravis He...,
  
• George Christopher Eliades,
  Director
• Donald J Santel,
  Director
• Enterprise Associates 14, L...,